Polar Capital Holdings’s Vera Therapeutics VERA Stock Holding History

Polar Capital Holdings’s Portfolio VERA Stock Details VERA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-675,000	Closed	-$24.4M	–	312
2024 Q2	$24.4M	Hold	675,000	–	–	0.14%	121
2024 Q1	$29.1M	Sell	675,000 -50,000	-7%	-$1.78M	0.15%	120
2023 Q4	$11.2M	Buy	+725,000	New	+$9.21M	0.07%	184

Other funds holding VERA

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Polar Capital Holdings's VERA Position: Q3 2024 in Review

Polar Capital Holdings sold out of Vera Therapeutics (VERA) in Q3 2024, closing a stake of 675,000 shares — an estimated $24.4M sold.

Polar Capital Holdings first reported a position in VERA in Q4 2023 and held it in 3 quarters. The position peaked at $29.1M in Q1 2024. 173 funds tracked by Wall St. Rank hold VERA as of Q3 2024.

Polar Capital Holdings reported no remaining Vera Therapeutics position as of Q3 2024 after selling out during the quarter.
Polar Capital Holdings sold 675,000 Vera Therapeutics shares in Q3 2024, an estimated $24.4M.
Polar Capital Holdings first reported a position in Vera Therapeutics in Q4 2023 and held it in 3 quarters.
Polar Capital Holdings's Vera Therapeutics position peaked at $29.1M in Q1 2024.
173 funds tracked by Wall St. Rank held Vera Therapeutics as of Q3 2024.

Based on Polar Capital Holdings's 13F filing for Q3 2024, filed 14 Nov 2024.